Literature DB >> 649230

The pharmacokinetics of dihydroergotamine in the beagle.

R Mäntylä, T Kleimola, J Kanto.   

Abstract

After single 0.5-mg nad 1.0-mg i.v. injections, dihydroergotamine, as measured by a radioimmunoassay, disappeared quickly from the plasma of beagles, with a mean alpha-phase half-life of 1.32--1.91 min. This explains its effect of rapidly lowering the temperature of the ear of the dog. Its short beta-phase half-life (mean, 40.79--70.13 min), a moderately low volume of ditribution at beta-phase (mean 1.50--3.46 L/kg) and a rather high plasma clearance value (mean, 311.67--587.88 ml/min) indicate a rapid elimination of the drug from the organism. The 24-hr urinary excretion of dihydroergotamine was 2.7% of the 0.5-mg i.v. dose and 2.3% to 3.1% of the 1.0-mg i.v. dose. A measure of the amount of a 7.5-mg p.o. dose of the drug reaching the systemic circulation was obtained from the ratio of the area under the plasma curve after p.o. administration to that after i.v. administration, corrected for the different amounts given by the two routes. Only 1.2--1.4% of the 7.5-mg p.o. dose of dihydroergotamine reached the systemic circulation. There were no significant differences in the plasma levels of dihydroergotamine after a single dose of the two preparations tested, Vasogin (Leiras) and Orstanorm (Sandoz), given either by the oral or intravenous route.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 649230

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  2 in total

1.  Bioavailability of dihydroergotamine.

Authors:  J Kanto
Journal:  Br Med J       Date:  1980-09-13

2.  Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing.

Authors:  H de Marées; D Welzel; A de Marées; U Klotz; K U Tiedjen; G Knaup
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.